Skip to content

Psilocybin and Psilocybe cubensis extract exhibit divergent behavioural and toxicological effects in rats

Diana Dias Da Silva, Andreia Machado Brito-da-costa, Francisco Sacadura, Mariana Carvalho, Helena Carmo, Ricardo Jorge Dinis-oliveira, Áurea Madureira-carvalho

Science Letters April 17, 2026 Peer reviewed DOI: 10.48797/sl.2026.497 via OpenAlex

Summary

Pure psilocybin caused a significant decrease in conditioned place preference scores at days 1 and 7, indicating aversive effects, while no significant changes were observed for the Psilocybe cubensis extract. The extract led to increased exploratory behavior at day 7 and reduced renal lipid peroxidation, suggesting protective effects. In contrast, psilocybin increased liver weight, indicating potential stress. These results highlight the different behavioral and toxicological profiles of pure psilocybin and mushroom extracts.

Study at a glance

Design randomized controlled trial
Sample size 18
Population male Wistar Han rats
Key finding Pure psilocybin significantly decreased conditioned place preference scores, indicating aversive effects, while the Psilocybe cubensis extract did not show significant preference changes.

Abstract

Background: Psilocybin, a key psychoactive compound found in Psilocybe mushrooms, has gained increasing attention due to its therapeutic potential in neuropsychiatric disorders [1]. However, comparative preclinical data between isolated psilocybin and whole mushroom extracts remain scarce, particularly regarding behavioural reinforcement and peripheral toxicity [2,3]. Objective: To compare the behavioural and toxicological effects of pure psilocybin and Psilocybe cubensis extract in Wistar Han rats. Methods: Male Wistar Han rats (n=18) were randomly assigned to control (0.9% NaCl), pure psilocybin (3 mg.kg⁻¹), or P. cubensis extract (equivalent to 3 mg·kg⁻¹ psilocybin/psilocin) groups. Treatments were administered orally. Behavioural effects were assessed using a conditioned place preference (CPP) paradigm, with evaluations at 1, 7, and 14 days post-treatment. Locomotor/exploratory activity was estimated by compartment entries. Peripheral effects were evaluated through relative organ weights and lipid peroxidation (TBARS assay) in the heart, brain, liver, and kidney. Statistical analysis was performed using ANOVA (p<0.05). All procedures were approved by the institutional Animal Welfare Committee and DGAV, in accordance with European and national legislation. Results: Pure psilocybin significantly decreased CPP scores at days 1 and 7, suggesting aversive or non-reinforcing effects, while no significant preference changes were observed for the extract. The extract group showed a transient increase in exploratory behaviour at day 7, whereas psilocybin-treated animals consistently displayed reduced entries in the drug-paired compartment. At the peripheral level, psilocybin increased relative liver weight, indicating potential hepatic stress or metabolic adaptation. In contrast, the extract reduced renal lipid peroxidation, suggesting a protective or antioxidant effect likely associated with additional bioactive compounds. Conclusions: Pure psilocybin and P. cubensis extract exhibit distinct behavioural and toxicological profiles. These findings highlight the relevance of matrix effects in psychedelic research and reinforce the need to consider whole-extract formulations when assessing safety and pharmacological outcomes.

Tags

Comments

No comments yet.

Log in to comment